- Home
- AUPH
as 12-17-2024 4:00pm EST
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
| Founded: | 1993 | Country: | Canada |
| Employees: | N/A | City: | EDMONTON |
| Market Cap: | 1.3B | IPO Year: | 1999 |
| Target Price: | $10.33 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.71 - $10.67 | Next Earning Date: | 11-07-2024 |
| Revenue: | $220,361,000 | Revenue Growth: | 38.72% |
| Revenue Growth (this year): | 36.97% | Revenue Growth (next year): | 16.43% |
Stock Insider Trading Activity of Aurinia Pharmaceuticals Inc (AUPH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| TANG KEVIN | AUPH | Director | Dec 5 '24 | Buy | $9.00 | 1,200,000 | $10,822,000.00 | 7,529,500 | |
| Smith Karen L. | AUPH | Director | Nov 8 '24 | Sell | $8.43 | 5,241 | $44,181.63 | 12,672 | |
| Bailey Jeffrey Allen | AUPH | Director | Nov 8 '24 | Sell | $8.43 | 4,557 | $38,415.51 | 13,356 |
Latest Aurinia Pharmaceuticals Inc News
AUPH Breaking Stock News: Dive into AUPH Ticker-Specific Updates for Smart Investing
Simply Wall St.
7 days ago
Exploring Three High Growth Tech Stocks In The United States
Zacks
8 days ago
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
MT Newswires
9 days ago
Aurinia Pharmaceuticals Insider Bought Shares Worth $10,822,000, According to a Recent SEC Filing
Simply Wall St.
12 days ago
While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership
Business Wire
a month ago
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Business Wire
a month ago
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
Business Wire
a month ago
Aurinia to Participate in Jefferies London Healthcare Conference
MT Newswires
a month ago
RBC Adjusts Aurinia Pharmaceuticals' Price Target to $9 From $8, Keeps Outperform Speculative Risk Rating
Compare AUPH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AUPH Aurinia Pharmaceuticals Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.